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The incidence of esophageal adenocarcinoma (EAC) has increased exponentially in the last 3 decades. Barrett’s esophagus (BE) is
the only known precursor of EAC. Patients with BE have a greater than 40 folds higher risk of EAC compared with the general
population. Recent years have witnessed a revolution in the clinical and molecular research related to BE. However, several
aspects of this condition remain controversial. Data regarding the true prevalence of BE have varied widely. Recent studies have
suggested a lower incidence of EAC in nondysplastic BE (NDBE) than previously reported. There is paucity of prospective data
showing a survival beneﬁt of screening or surveillance for BE. Furthermore, the ever-increasing emphasis on healthcare cost
containment has called for reexamination of the screening and surveillance strategies for BE. There is a need for identiﬁcation
of reliable clinical predictors or molecular biomarkers to risk-stratify patients who might beneﬁt the most from screening or
surveillance for BE. Finally, new therapies have emerged for the management of dysplastic BE. In this paper, we highlight the key
areas of controversy and uncertainty surrounding BE. The paper discusses, in detail, the current literature about the molecular
pathogenesis, biomarkers, histopathological diagnosis, and management strategies for BE.
1.Introduction
In the last 3 decades, the incidence of esophageal adenocarci-
noma(EAC)hasincreasedatafasterratethananyothercan-
cer in the US and Western Europe [1–4]. Despite advances
in therapies, the 5-year survival rate for EAC remains less
than 15% [5]. Barrett’s esophagus (BE), a condition in which
the squamous epithelium of the distal esophagus is replaced
by columnar epithelium with intestinal metaplasia (IM), is a
well-established precursor of EAC. BE increases the risk of
EAC by greater than 40-fold compared with the general
population [6, 7]. Our understanding of BE has increased
signiﬁcantly over the past half a century. However, many
aspectsofthenaturalhistoryandpathophysiologyofBEhave
not been fully elucidated.
Some of the controversial areas of BE include the
following:
(i) There is a lack of consensus regarding the deﬁnition
of BE and whether IM should be a requirement for
the diagnosis of BE [8–10].
(ii) True prevalence of BE in the general population and
its risk of progression to EAC remain unclear. Recent
studies have suggested a lower risk of malignant
transformation of BE than previously reported [11–
14].
(iii) A clear survival beneﬁt of screening or surveillance
f o rB Eh a sn o tb e e nd e m o n s t r a t e di np r o s p e c t i v e
studies [8].
(iv) There is a lack of reliable predictive biomarkers that
might enable us to risk-stratify BE patients and iden-
tify those who would beneﬁt the most from endo-
scopic surveillance and therapy [15].
The aim of this paper is to review the current evidence
related to the deﬁnition of BE, the cancer risk of non-
dysplastic and dysplastic BE, screening and surveillance for
BE, management of dysplasia in BE, and chemo-preven-
tion of BE. The molecular pathogenesis, biomarkers, and
histopathological diagnosis of BE will also be discussed in
detail.2 Pathology Research International
2. HistoricalPerspectiveand Deﬁnition of
Barrett’sEsophagus
In 1950, Norman Barrett, an Australian-born, British sur-
geon suggested that the ﬁnding of gastric-type mucosa in
the esophagus was in most cases, due to a congenitally
shortened esophagus resulting in extension of the stomach
into the mediastinum. He proposed that ulcers occurring in
these areas (described as “peptic ulcers of the oesophagus” by
most pathologists of that era) were a diﬀerent entity than
the ulcers and strictures of the esophagus that occur as a
result of acid reﬂux. He coined the term “reﬂux oesophagitis”
for the latter disease process [17]. In 1953, Allison and
Johnstone published an article titled “The oesophagus lined
with gastric mucous membrane” to emphasize that the areas
of columnar mucosa described by Barrett were actually part
oftheesophagusandnotstomach.Theyproposedthatulcers
in these areas be called “Barrett’s ulcers” [18]. Seven years
after his original article, Barrett agreed with Allison and
Johnstone and suggested that these ﬁndings be called the
“lower oesophagus lined by columnar epithelium” [19]. With
time, the replacement of the normal squamous lining of
the esophagus by columnar epithelium became known as
“Barrett’s oesophagus” [20].
I nN o r t hA m e r i c a ,B Ei sd e ﬁ n e da sac h a n g ei nt h e
distal esophageal epithelium of any length, recognized as
columnar-type epithelium on endoscopy, and conﬁrmed
to have IM by biopsy of the tubular esophagus [8, 21].
However, diﬀerences of opinion surround this deﬁnition.
There is a lack of consensus regarding the precise anatomical
landmarks deﬁning the distal limit of esophagus (gastroe-
sophageal junction (GEJ)). According to one school of
thought, the GEJ is at the proximal aspect of gastric mucosal
folds. However, these landmarks can shift during phases
of respiration, distension of the stomach and esophagus,
and gut peristalsis [22]. Others consider GEJ as the distal
end of the palisade vessels in the lamina propria of the
esophagus. This landmark can be obscured by pathology
in the distal esophagus and lends itself to interobserver
variability [23, 24]. Three types of columnar epithelia can
be seen on biopsies from Barrett’s like mucosa: (a) cardia
type metaplasia composed of mucin secreting glands, (b)
gastric-fundus-type metaplasia comprising of parietal cells,
chief cells, and mucus secreting cells, and (c) specialized
IM, containing predominantly goblet cells. The ﬁrst 2 types
can be indistinguishable from the gastric mucosa, unless the
biopsy specimen contains esophageal submucosal glands or
islands of squamous epithelium [25]. If cardia- or fundic-
type mucosa are obtained from the biopsies from the distal
esophagus, the possibility of inadvertent sampling from the
stomach should be considered. Conversely, IM can be seen in
gastric biopsies due to Helicobacter pylori infection. To add
to the complexity of this issue, studies have shown that 10–
15% of normal population can have IM in the gastric cardia
or GEJ [26–28]. Therefore, even the presence of IM does not
completely rule out sampling error [28].
If predisposition to EAC is an essential tenet of BE, do
all of the 3 types of columnar metaplasia described above
increase the risk of EAC? There is robust scientiﬁc evidence
Table 1: Deﬁnition of Barrett’s esophagus proposed by major
professional organizations of various countries [8, 9, 21, 42].
ACG
(USA)
AGA
(USA)
BSG
(England)
SFED
(France)
Endoscopic
documentation of
columnar lined mucosa in
the tubular esophagus
required
Yes Yes Yes Yes
IM required on biopsies
from the tubular
esophagus
Yes Yes No Yes
ACG:AmericanCollegeofGastroenterology;AGA:AmericanGastroentero-
logical Association; BSG: British Society of Gastroenterology; SFED: French
Society of Digestive Endoscopy.
that IM increases the risk of EAC [3, 29]. Some studies
have suggested that cardia-type (nongoblet) metaplasia may
also predispose to EAC, perhaps to a lesser extent [30,
31]. However, the true population-based risk of progression
of nongoblet metaplasia to EAC is not known. There is
scant scientiﬁc evidence at this time to include nongoblet
metaplasia in the deﬁnition of BE.
There is also a lack of consensus among various profes-
sional organizations whether goblet metaplasia, that is, IM,
should be a requirement for diagnosis of BE (also see related
discussion below, in the section on histopathology). The
British Society of Gastroenterology (BSG) no longer considers
IM as a diagnostic criterion for BE [9]. Experts in favor of
this school of thought contend that the yield of IM drops as
the length of columnar lining and number of biopsies taken
decrease [32, 33]. Multiple biopsies must be obtained to
adequately assess for IM in patients with >1cmofcolumnar
lined esophagus [34]. Several arguments can be made in
favor of requiring IM for a diagnosis of BE. Studies suggest
that a diagnosis of BE may have a negative impact on overall
quality of life of the patients. Patients with BE tend to
overestimate their risk of cancer, and this leads to higher
utilization of healthcare resources. A diagnosis of BE can
result in higher health insurance premium and diﬃculty in
obtaining health insurance [35–37]. The American College of
Gastroenterology (ACG)andtheAmericanGastroenterological
Association (AGA) recommend documentation of IM for a
diagnosis of BE [8, 21]. Table 1 summarizes deﬁnition of BE
proposed by major professional organizations.
Historically, BE has been classiﬁed into short-segment
(<3cm) and long-segment BE (≥3cm), based on the length
of metaplastic epithelium seen on endoscopy [38]. A more
recent classiﬁcation takes into consideration the circumfer-
ential (C) and maximum (M) extent of the endoscopically
visualizedBE,abovetheGEJ.This systemiscalledthePrague
“C” and “M” criteria (Figures 1(a), 1(b) and 1(c)). The
original C&M criteria were developed by an international
working group using videoendoscopic recordings in 29
patients. To validate these standardized criteria, a separate
panel of 29 expert endoscopists scored these recordings. The
overall reliability coeﬃcients (RCs) for the assessment of C
and M extent were 0.95 and 0.94, respectively. The RCs forPathology Research International 3
GEJ at 38 cm from incisors
Circumferential extent of BE∗ at
36 cm from teeth
Maximum extent of BE∗ at
34 cm from incisors
C = 2cm
M = 4cm
Stomach
Esophagus
Depth of scope insertion (cm) Distance from GEJ (cm)
Prague criteria
(a)
M = 4
C = 2
(b)
(c)
Figure 1: (a) Schematic representation of the Prague criteria for endoscopically suspected esophageal columnar metaplasia/Barrett’s
esophagus,Step1:recognizethepresenceofhiatalhernia;Step2:identifyGEJandrecorddepthofscopeinsertion;Step3:recognizesuspected
BE mucosa above the GEJ; Step 4: record the depth of scope insertion at the most proximal circumferential extent of BE; Step 5: record the
depth of scope insertion at maximum extent of BE; Step 6: subtract the depth of insertion for circumferential and maximum extents from
the depth of scope insertion at the GEJ to calculate C and M, respectively. ∗Endoscopically suspected columnar mucosa. Adapted from
[16]. (b) endoscopic image of Barrett’s esophagus for circumferential (C) and maximum (M) extent of columnar mucosa, corresponding
to the schematic representation shown in Figure 1(a), (c) another endoscopic image of BE using narrow-band imaging (NBI). NBI is a
high-resolution endoscopic tool that enhances mucosal surface details without the need for special dyes (electronic chromoendoscopy).
recognizing the location of the GEJ and the diaphragmatic
hiatus were 0.88 and 0.85, respectively [16]. A recent
multicenter study of gastroenterology trainees demonstrated
correlation coeﬃcients of 0.94 and 0.96, respectively, for
assessment of the C and M extent of the endoscopically
visualized BE. The correlation coeﬃcients for recognition of
GEJ and diaphragmatic hiatus were 0.92 and 0.90, respec-
tively [39]. Kinjo et al. prospectively compared endoscopic
BE diagnoses using the Japanese criteria (GEJ deﬁned as
the distal limit of the longitudinal or palisade vessels in the
laminapropriaoftheesophagus)andPragueC&Mcriteriain
110 Japanese patients. A higher proportion of patients were
diagnosed with endoscopic BE using the Japanese criteria
(39%) compared with C&M criteria (26%) (P = 0.044).
The GEJ identiﬁcation rates were also higher using the
Japanese criteria than with C&M criteria (95% versus 86%
(P = 0.039)). The authors concluded that, in the Japanese
population,theJapanesecriteriamaybemoresuitableforthe
diagnosis of endoscopic BE and for recognition of GEJ than
the C&M criteria. The important limitations of this study
are that only 2 endoscopists interpreted the ﬁndings, and the
study was not designed to assess interobserver correlation
for the 2 criteria [40]. No formal studies have evaluated
the “clinical beneﬁt” of using any standardized classiﬁcation
for the assessment of the endoscopic extent of BE segment.
However, data suggest a direct relationship between the
endoscopic extent of BE and the probability of ﬁnding IM on
histology. Greater BE surface area may translate into greater
cancer risk [29, 41]. Major professional societies recommend
that information about the extent of metaplasia should be
recorded using standardized methods [8, 21].
3. Epidemiology and ClinicalFeatures
BE is usually detected on upper endoscopy for various
indications, during the 6th decade of life or later [51, 52].
The male-to-female ratio for BE is approximately 2:1 [53].4 Pathology Research International
White subjects have a 4–6 times higher incidence of BE
compared to black subjects [2, 12, 51, 54]. Patients with
chronic heart burn are 6–10 times more likely to have BE
than those without heartburn [55–57] .Ah i g hb o d ym a s s
indexandacentripetaldistributionofbodyfatalsoincreased
the risk of BE in multiple studies [58–61]. Data suggest that
Helicobacter pylori infection, red wine, and diet rich in fruits
and vegetables may have protective eﬀectagainstBE [62–67].
The reported prevalence of BE in diﬀerent studies has
varied widely, depending on the population studied and
the deﬁnition used. A study of 733 unselected autopsies
from Olmsted county, MN, USA, estimated the prevalence
of BE to be 376 per 100,000 population [68]. A retrospective
analysis of a US rural white population in the Marshﬁeld
Epidemiologic Study Area (MESA), estimated the prevalence
ofendoscopicallyandhistologicallyconﬁrmedBEtobe261.8
per 100,000 persons [69]. BE was diagnosed in 6.8% patients
in a study of 961 US patients who were scheduled for a
colonoscopyandhadnopriorhistoryofanupperendoscopy.
However, the study population comprised of predominantly
white males [12]. There is a lack of large population-based
studies on the prevalence of BE in the United States. A
Swedish study reported the prevalence of BE to be 1.6%,
when both endoscopic and histological criteria were used to
deﬁne BE [70].
Thepresenceofcolumnarmucosainthedistalesophagus
does not cause symptoms per se. The symptoms in these
patients are mostly related to sequelae of long-standing
gastroesophageal reﬂux disease (GERD) (e.g., esophagitis,
peptic stricture, etc.). Absence of chronic reﬂux symptoms
does not exclude the possibility of BE. Indeed, in the Swedish
study, about 44% of the patients found to have BE did not
report signiﬁcant symptoms of heart burn and dyspepsia
[70]. BE is seen in about 10–15% of the patients undergoing
upper endoscopy for chronic GERD, and in 5.6% of those
without chronic reﬂux symptoms [71]. The frequency of
long-segment BE is 3–5% and short-segment BE is 10–15%
among patients with chronic GERD [72].
4. The Pathogenesis of Barrett’sMetaplasia
4.1. Cell of Origin. A very important step in understanding
the development of BE and its progression to EAC is
identifying the cell of its origin. Unfortunately, the cell of
origin in BE is not known. There exist currently 2 conﬂicting
hypotheses. The ﬁrst possibility is that BE arises from a stem
cell. To complicate this question further, the origin of this
putative stem cell is also up for debate. It is possible that
the BE stem cell originates from the stratiﬁed squamous
epithelium compartment, the submucosal glands of the
distalesophagus,bone-marrow-derivedstemcells(BMDCs),
or stem cells located in the proximal stomach [73–77].
Search for a putative BE stem cell is hindered by the lack of
knowledge regarding stem cells of the esophagus. To date,
only one group has identiﬁed a population of squamous
epithelial-derived cells enriched for stem cell properties
which can be isolated by ﬂow cytometry sorting for CD34,
a marker for stem cells in other tissues [78].
A second hypothesis for the cell of origin of BE is that of
ad i ﬀerentiated esophageal keratinocyte. One presumption
for this hypothesis would be that the squamous epithelium
would undergo at least a partial dediﬀerentiation. Recent
work to generate pluripotent-induced progenitor stem cells
(iPS) by introduction of c-myc, KLF4, Sox2, and Oct3/4 into
adult ﬁbroblasts has lent credence to this possibility [79]. In
fact, several of these genes have been demonstrated to play a
role in esophageal and BE biology. Sox2 has been determined
to be a lineage-speciﬁc transcription factor in the esophagus
specifying squamous cell diﬀerentiation [80]. KLF4 and c-
myc expressions are upregulated in Barrett’s esophagus and
may contribute to a transdiﬀerentiation process [81, 82].
Further work on stem cells and the molecular pathways
involved in the transdiﬀerentiation process of BE will be
necessary to address the cell of origin question.
4.2. Reﬂux Exposure and Inﬂammation. One of the most
stronglyassociatedclinicalsymptomsforthedevelopmentof
BEistherecurrentreﬂuxofacidandbilesalts.Epidemiologic
data suggests that GERD is important for the development
of BE [83]. Approximately 13% of patients that have been
diagnosed with GERD develop BE [84]. These data suggest a
role for GERD in the development of BE. In fact, surgical
anastomosis of the esophagus to the small intestine by
either joining to the duodenum (EDA or EGDA models) or
jejunum (EJA) in rats has veriﬁed this hypothesis [85–87].
The chronic reﬂux associated with GERD induces a
signiﬁcant amount of epithelial damage and a commensu-
rate inﬂammatory response. Research over the last several
decades has begun to illustrate the role inﬂammation plays
in many disease processes, and this is likely true with the
development of BE and esophageal adenocarcinoma. Work
has focused on cytokines secretion in BE, signaling events
induced in the esophageal epithelium in response to GERD,
andtheaccompanyinginﬂammationthatmayberesponsible
for the metaplastic process in BE cells. Acid and bile salt
exposure may impair the barrier function as well [88].
This loss of barrier function and damage to the epithelium
may be the precipitating events for the initial inﬂammatory
response. This induces a Th2 inﬂammatory response replete
with the expression of IL1β, IL4, IL6, IL8, TNFα,a n dI F N γ
[89]. This type of a response has been associated with tumor
formation and progression by recruiting immature myeloid
cells, tumor-associated macrophages, and neutrophils [90–
94]. This type of immune response may have a similar role
in triggering signaling events that result in metaplasia of the
epithelium.
Several signaling pathways associated with inﬂamma-
tion have been implicated in BE. Cyclooxygenase (Cox)
gene expression appears to be induced by acid reﬂux. In
fact, its expression level is positively correlated with the
degree of acid reﬂux which occurs in a given patient.
Interestingly, Cox2 expression increases as BE progresses to
EAC, suggesting that Cox2 may functionally contribute to
the pathogenesis of EAC [95]. Indeed, epidemiologic data
demonstrate that anti-inﬂammatory treatment decreases
cancer risk due to Cox2 inhibition [96, 97].Pathology Research International 5
In addition to Cox genes expression, NFκB expression
has also been implicated in the initial stages of the devel-
opment of BE. Induction of NFκB in esophageal cells sub-
sequent to inﬂammation-inducing reﬂux many have eﬀects
withintheepitheliumincludingtheinductionofcellsurvival
pathways as well as the transcription of target genes involved
in the development and progression of BE. Indeed, NFκBh a s
been demonstrated to be a direct transcriptional regulator of
the caudal, homeodomain-containing transcription factors,
Cdx1 and Cdx2 [98, 99]. Cdx genes have been implicated in
the earliest stages in the transdiﬀerentiation process of BE
[81].
5. Biomarkers of Barrett’s Esophagus
Genome-wide examination of BE lesions had been per-
f o r m e di no r d e rt oc h a r a c t e r i z eB Ef o rg e n ee x p r e s s i o n
changes when compared to normal esophagi, EAC, gastric
epithelia, gastric cancers, small intestinal epithelia, and
colonic epithelia. The use of microarray expression analyses
has generated a large amount of data characterizing the dif-
ferences between these tissues. Many of the arrays have iden-
tiﬁed genes that function in cell growth and proliferation,
apoptosis, cell metabolism, lipid metabolism, catabolism,
celladhesion,signaltransduction,migration,stressresponse,
cell adhesion, signal transduction, and transcription factors
[100–106]. While these lists cover a wide array of cellular
functions, many of these categorizations seem logical based
on what is currently known about BE.
One interesting publication describes the identiﬁcation
of two distinct subcategories of BE dubbed as BE1 and BE2
[102]. BE1 identiﬁes a group similar to that of normal stom-
ach mucosal samples and includes several tumor suppressor
genes. BE2 identiﬁes a group that may lie closer to EA than
does BE1. BE2 gene expression contains genes that have
been either overexpressed in cancers such as carboxylesterase
2, galectin-4, glycoprotein A33, and LI-cadherin. These
classiﬁcations of diﬀerent BE samples are intriguing and
may be reﬂected in two other microarray studies. One study
from Barrett et al. subclassiﬁed BE samples into several
categories including their own BE1 group which had a
higher correlation coeﬃcient with squamous samples while
sample their BE4 group had a higher correlation with their
gastric samples [100]. A third study from the University of
Pennsylvania suggested that two populations of BE may exist
[81]. Principle component analysis placed BE samples into
2 groups spatially that were distinct from each other yet
closely related based on global gene analysis. A meta-analysis
of all BE samples to determine if classiﬁcations extend
beyondthesedatasetswouldbeveryinformative.Diﬀerences
between BE groups may identify biomarkers that would
predict progression. Several microarray expression analyses
havebeguntoidentifygenesthatmaypredicttheprogression
of BE to EAC [103, 104, 106]. These genes include MMP7,
CXCL3, GATA6, HoxB7, and SPRR3. Pepe et al. have deﬁned
ﬁve phases of biomarker development to establish a gene as a
bone ﬁde biomarker of disease [107]. Few biomarkers have
been evaluated for risk stratiﬁcation using this systematic
approach in BE. Unfortunately, most of the microarray data
publishedtodatehavelackedfollowupworktoidentifythose
genes contained within the data sets that contribute to the
cause of BE or its progression to EAC or in the alternative to
serve as true biomarkers for disease progression.
6.SignalingPathways
As had been previously discussed, many factors such as acid,
bile salts, and inﬂammation are likely to contribute to the
pathogenesis of BE. What remains less well deﬁned are the
intracellular signaling events responsible for the transition to
BE which is likely due to several signaling pathways altering
the diﬀerentiation of the epithelium of the esophagus. As
a result, an approach whereby several signaling pathways
are manipulated at one time is needed. As previously
mentioned, Cdx gene expression has been detected in BE
and is likely a result of NFκB expression subsequent to the
inﬂammatory response elicited by acid reﬂux. Indeed, Cdx
gene expression is one of the most likely candidates for
transcription factors that induce intestinal metaplasia due to
its well-established role in embryonic intestine development.
Additional signaling events that may induce Cdx expression
are retinoic acid (RA) and hedgehog signaling [108–112].
Another transcription factor, c-myc, is important for
the development of BE [81, 113]. Interestingly, c-myc
expression increases in dysplastic lesions and reaches its
highest expression in EAC. Also, c-myc activation has been
implicated in BE by microarray analysis [81]. To test whether
c-myc was involved in BE, c-myc was coexpressed with Cdx1
in squamous esophageal cell lines and induced several genes
expressed in BE, suggesting a partial shift in diﬀerentiation.
7.Histopathology Diagnosisand
DysplasiaGrading
7.1. Deﬁnition: Intestinal Metaplasia or No Intestinal Meta-
plasia. As discussed above, the deﬁnition of BE varies
worldwide[114].CountriessuchasUSArequirethepresence
of goblet cells (IM), whereas England and Japan accept
any endoscopically visible columnar metaplasia as suﬃcient
to deﬁne BE. The requirement of IM has been supported
by studies that have claimed IM to be a prerequisite
for the development of adenocarcinoma [115, 116]. More
recently, there has been a suggestion to move away from
this view [10]. Gatenby et al. evaluated clinical followup for
934 patients, including 322 with intestinal metaplasia and
612 with nongoblet columnar cell metaplasia of the distal
esophagus, and found no diﬀerence with respect to dysplasia
and/or cancer incidence between the two groups (19.8%
versus 15.2%, resp.), suggesting that nongoblet glandular
epithelium in the distal esophagus may also be at risk for
neoplastic transformation [117]. As suggested by DeMeester,
a practical approach may be to consider that patients with
≥3cm of columnar-lined esophagus nearly always either
have or will develop IM, and these patients should be
considered to have BE along with those with shorter lengths
of columnar mucosa who show IM on biopsy [118].6 Pathology Research International
Goblet cells may be identiﬁed on routine histological
stains (hematoxylin and eosin, H&E), although many insti-
tutions routinely employ PAS-Alcian blue stains to highlight
acidic mucin in goblet cells (blue by Alcian blue at pH
2.5) against a backdrop of gastric neutral mucin (magenta
caps by PAS). This stain is helpful in diﬀerentiating true
IM from so-called columnar blue cells or pseudogoblet cells,
which are gastric foveolar cells that have been “injured” by
acid reﬂux disease. The Alcian blue stain also helps in easy
identiﬁcation of IM and saves time in evaluating a biopsy.
Another clue to the presence of IM is the presence of so-
called “multilayered epithelium” which is characterized by
the presence of an overlay of columnar cells over basal layers
of squamous cells. In their study of 17 cases, Glickman et al.
found that glandular cells of multilayered epithelium express
diﬀerentmucintypeswithsimilar frequenciestoIMandalso
frequently express CDX2 and MUC2, similar to goblet cells
thatoccurintheesophagus.Theyproposedthatmultilayered
epithelium is a precursor to intestinal metaplasia; presence
of multilayered epithelium should prompt a more detailed
search for goblet cells [119].
The IM of gastric cardia mucosa does not equate to BE,
since BE has to involve the tubular esophagus. Also, IM
of gastric cardia may be less likely to progress to dysplasia
than true BE [120]. Thus a diagnosis of BE cannot be made
histologically when the exact site of biopsy of the metaplastic
fragment is not known. BE is a clinicopathologic diagnosis
and the biopsy must be from an endoscopically visualized
abnormality in the tubular esophagus. IM may be either
“complete”(whengobletcellsareaccompaniedbyabsorptive
and/or Paneth cells) or “incomplete” (absence of absorptive
and/or Paneth cells). Conceptually speaking, incomplete
IM is less diﬀerentiated and therefore more likely to be a
dysplasiaprecursor.Inpractice,incompleteandcompleteIM
may exist adjacent to each other, and their identiﬁcation may
purely be a result of sampling. Hence, subtypes of IM are not
generally mentioned in pathology reports.
7.2. Dysplasia: Negative and Indeﬁnite. All biopsies for
BE diagnosis and surveillance should include a qualiﬁer
regarding presence or absence of dysplasia. Dysplasia is
assessed in columnar mucosa, preferably away from squa-
mousmucosa,andwherethesurfacelining is intact.Biopsies
are categorized as being “negative for dysplasia” if the
cells show maturation towards the surface in the form of
decreasing nuclear size, decreasing nuclear hyperchromasia,
increasing cytoplasmic volume and a mucus cap on surface
cells (Figure 2(a)). In some cases, there may be some changes
that are deemed insuﬃcient to characterize as dysplasia,
and these are categorized as “indeﬁnite for dysplasia”. Cases
that are classiﬁed as being indeﬁnite for dysplasia are either
those with minimal to mild cytologic atypia or those that
have more than mild cytologic atypia but are accompanied
by signiﬁcant inﬂammation, raising a possibility of atypia
reactive to the inﬂammatory response. These cases need
rebiopsy after control of inﬂammation. Reactive changes
tend to be more diﬀuse rather than abrupt, the latter being a
feature of dysplasia. The category of “indeﬁnite” should not
be used to downgrade dysplasia, but rather to identify cases
that may need followup biopsies.
7.3. Dysplasia: Intestinal Type. Most dysplasias occurring in
a setting of IM are of the “intestinal type.” Criteria used
to classify dysplasia in this setting are similar to what has
been used in colonic adenomas. This pattern of dysplasia
is therefore morphologically recognized by the presence
of hyperchromatic elongate nuclei, with lack of surface
maturation and presence of nuclear crowding, such that the
surface epithelium appears generally similar to the glands
at the depth. In low-grade dysplasia (LGD), architecture is
by and large preserved, true nuclear stratiﬁcation is absent,
and, as a rule, nuclear polarity is maintained (Figure 2(b)).
Changes are usually patchy or focal with relatively abrupt
transformation between dysplastic and nondysplastic foci,
although this transition may not always be evident.
High-grade dysplasia (HGD) is usually identiﬁable at
low-power examination by architectural abnormalities such
as glandular crowding, branching, and complexity. Nuclear
atypia is also more pronounced, with increasing nuclear
stratiﬁcation and nuclei reaching the surface of the lin-
ing cells, without a clear cytoplasmic zone at the apex
(Figure 2(c)). There is chromatin smudging, increasing
nuclear irregularity, and presence of surface mitoses. Loss of
nuclear polarity is the single most helpful feature to identify
HGD at the cytologic level. In a setting of HGD, presence
of cribriform (“back to back”) glands, luminal necrosis,
glandular budding, and incomplete glands may indicate
intramucosal carcinoma (Figure 2(d))[ 121].
7.4. Dysplasia: Basal Crypt Dysplasia and Foveolar Dysplasia.
Basal crypt dysplasia was recently described as another
variant of dysplasia. This entity is recognized by the
presence of dysplasia-like atypia aﬀecting the deep/basal
crypts with the presence of surface maturation. Lomo et al.
consider this to be true dysplasia in view of the presence
of molecular abnormalities (signiﬁcantly increased rate of
17p (TP53) LOH and aneuploidy), and a high association
with conventional dysplasia and/or adenocarcinoma, despite
the morphologic appearance of surface maturation. The
clinical, pathologic, immunohistochemical, and molecular
abnormalities were similar in cases showing low-grade and
high-grade histological changes in the basal crypts, except
that high-grade cases tended to occur in older patients
[122]. Presently, there are no clear guidelines on followup of
patients with basal crypt dysplasia. Many pathologists tend
to diagnose these cases as indeﬁnite for dysplasia with a
comment that dysplasia is restricted to the basal crypts.
Gastric foveolar-type dysplasia is another distinct variant
of dysplasia in BE. This dysplasia is similar to the so-called
type II dysplasia that is known to occur in the stomach
[123, 124]. The diagnosis of gastric foveolar-type dysplasia
in BE can be challenging, since there are no standardized
diagnostic or grading criteria. Mahajan et al. evaluated
the prevalence, morphology, and natural history of gastric
foveolar-type dysplasia in a cohort of 200 BE patients. The
prevalence of gastric foveolar-type dysplasia was 15% at thePathology Research International 7
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Figure 2: (a) Intestinal metaplasia is deﬁned by the presence of goblet cells distended with mucin. In this photomicrograph there is no
dysplasia, as evidenced by presence of surface maturation. Surface epithelial cells show uniform mucin caps and well-polarized nuclei. (b)
Low-grade dysplasia of the intestinal type is characterized by hyperchromatic elongate nuclei that are seen in both the crypts and the surface
epithelium (i.e., loss of surface maturation). (c) Presence of glandular crowding, nuclear stratiﬁcation, and loss of nuclear polarity signiﬁes
high-grade dysplasia. (d) Glandular complexity, budding, and presence of incomplete glandular proﬁles are evidence of lamina propria
invasion (intramucosal carcinoma).
patient level and 20% at the biopsy level. Unlike intestinal-
type dysplasia, gastric foveolar-type dysplasia uniformly
showed nonstratiﬁed, basally oriented nuclei, explaining
the diﬃculty in its recognition. This uniformity therefore
precludes the use of loss of nuclear polarity in identifying
HGD within this group. Rather, the most important feature
permitting a diagnosis of high-grade gastric foveolar-type
dysplasia was signiﬁcantly increased nuclear size (to approx-
imately 3-4 times the size of a mature lymphocyte). Other
featuresinhigh-gradelesionsincludedvilliformarchitecture,
crowded, irregular glandular architecture, eosinophilic and
oncocytic cytoplasm, prominent nucleoli, and mild nuclear
pleomorphism. During followup, 64% (7 of 11) of patients
with pure gastric and 26% (5 of 19) with mixed gastric and
intestinal dysplasia underwent neoplastic progression [125].
7.5. Interobserver Variation in Dysplasia Grading. Given the
subjectivity in identifying and grading dysplasia, it is not
surprising that there is a fair amount of interobserver
variability in the pathologic evaluation of BE biopsies. In
a study by Kerkhof et al., general pathologists were found
to overdiagnose HGD [126]. Nearly 40% of patients who
were initially diagnosed with HGD by a general pathologist
were downgraded (11% no dysplasia, 12% indeﬁnite for
dysplasia, 16% LGD) when the samples were reviewed by
three experienced gastrointestinal (GI) pathologists. Downs-
Kelly et al., however, reported overall poor interobserver
reproducibility even among GI pathologists who see a high
volume of Barrett’s cases, calling into question treatment
regimens based on the assumption that HGD, intramu-
cosal adenocarcinoma, and submucosal adenocarcinoma
can reliably be distinguished in biopsy specimens [127].
Montgomery et al. evaluated reproducibility of diagnoses
among expert GI pathologists and found that reproducibility
improvedonlyafteraconsensusmeetingtodecideoncriteria
to be used. Interobserver variation was better for clinically
relevant separation into two groups (BE indeﬁnite and
LGD; versus HGD and carcinoma), than into four groups
(BE; indeﬁnite and LGD; HGD; carcinoma). Agreement
was least for distinction between indeﬁnite and low-grade
categories [128]. Followup data collected on 138 cases from
the above study were separately analyzed. Dysplasia grade8 Pathology Research International
on initial biopsy correlated signiﬁcantly with progression to
invasive carcinoma. Using the initial submitting diagnoses,
carcinomas were detected on followup in 18% of indeﬁnite,
15% of LGD, and 61% of HGD cases. When majority
diagnoses (among 12 GI pathologists) were used for analysis,
carcinomas were detected in 14% indeﬁnite, 20% of LGD,
and 60% of HGD cases. There were 39 cases without a
majority diagnosis, among which carcinomas were detected
in 43% cases with an average score between indeﬁnite and
LGD and 70% cases with an average score between LGD
and HGD [129]. Interestingly, interobserver reproducibility
for basal crypt dysplasia has been reported to be better than
conventional LGD but poorer than that for HGD and BE
without dysplasia [130]. Notwithstanding the relative lack
of reproducibility, it is opined that, in general, pathologists
perform extremely well when diagnosing lesions of the
highest and lowest risk [131].
7.6. Dysplasia: Role of Immunohistochemistry. Studies have
also addressed the utility of immunohistochemical markers
in identifying and grading dysplasia. Immunohistochemistry
for p53 has been reported to assist in diagnosis in diﬃcult
cases [132]. Immunohistochemistry for p53 and Ki67 has
also been reported to correlate with the severity of dysplasia
in assessing Barrett’s biopsies [133, 134]. In another study
of 86 biopsies, protein overexpression of β-catenin helped
diagnose LGD, whereas overexpression of cyclin D1 and
p53 discriminated HGD from LGD [135]. However, most
pathologists rely on routine stains and morphology to
diagnose and grade dysplasia and immunohistochemistry is
rarely, if ever, used in routine day-to-day practice in most
centers.
8. Risk of Progression of Nondysplastic
Barrett’s to Esophageal Adenocarcinoma
Initial studies observed that the risk of progression of BE to
E A Cr a n g e db e t w e e n2a n d4 %p e ry e a r[ 136–138]. Shaheen
et al. noted that these studies might have overestimated the
riskduetopublicationbiasinfavorofsmallerstudiesreport-
ing relatively higher incidence [139]. Data from subsequent
studies showed a lower risk. A meta-analysis of 41 studies
with a total followup of 36,635 person years showed 0.7%
annual risk of progression from BE to EAC. There was no
evidenceofsigniﬁcantgeographicvariationbetweenUS,UK,
and Europe. There was a trend towards decreased risk of
EAC in short-segment BE [29]. Another exhaustive review
of forty-seven studies reported a pooled annual estimate of
0.61% for cancer incidence in patients with BE. When early-
incident cancers were excluded, the risk decreased to 0.53%
per year. When both early incident cancers and HGD at
baseline were excluded, the risk was noted to be 0.41% per
year [3].
More recent studies have suggested a lower risk of
progression of BE to EAC. Bhat et al. analyzed data on
8522 patients with BE from the Northern Ireland Barrett’s
esophagus register (NIBR). The mean followup was 7 years.
Incidence of EAC, carcinoma of the gastric cardia, and HGD
was reported to be 0.22% per year in the entire study cohort.
Of note, this study used the British deﬁnition of BE whereby
IM was not required for diagnosis of BE. The incidence of
EAC, carcinoma of the gastric cardia, and HGD in patients
with IM on index biopsies (criteria used in the US) was
0.38% per year versus 0.07% in those without IM (HR =
3.54, 95% CI = 2.09 to 6.00, P<0.001). The risk was
signiﬁcantly higher in males versus females (HR = 2.11)
[7]. A recent study from Denmark reported the incidence
of EAC to be 0.29% per year when 11,028 patients with BE
were followed for 67,105 person-years. When the EAC cases
diagnosed within ﬁrst year of followup were excluded, the
overall annual incidence decreased to 0.12%. The incidence
of EAC was 0.1% per year among patients with NDBE on
index endoscopies [14].
9. Risk of Progression of
Nondysplastic Barrett’stoAdenocarcinoma
of the GastricCardia
Data suggest that chronic reﬂux and BE increase not only the
risk of EAC but also that of adenocarcinoma of the gastric
cardia. Ruol et al. compared the epidemiological, clinical,
and pathological characteristics of 26 patients with EAC
in BE and 16 patients with adenocarcinoma of the gastric
cardia. They observed that IM was present in the mucosa
adjacent to 25/26 (96%) patients with EAC in BE, and 11/16
(69%) patients with adenocarcinoma of the gastric cardia.
Authors concluded that IM may be a common precursor of
adenocarcinoma in BE and adenocarcinoma of the gastric
cardia [116]. In a retrospective study of the pathology
specimen of 100 patients who underwent esophagectomy for
adenocarcinoma of the esophagus, cardia, or proximal stom-
ach,specializedIMwasidentiﬁedintheresectedspecimenin
13/31 (42%) of patients with adenocarcinoma of the cardia
asopposedto1/21(5%)inthosewithadenocarcinomaofthe
proximal stomach [140]. In the Northern Ireland Barrett’s
esophagus registry, 16 incident cases of adenocarcinoma of
the gastric cardia were reported during a mean followup of
7 years in 8522 patients [7].
10. Risk of Progressionof DysplasticBarrett’s
to Esophageal Adenocarcinoma
10.1. Risk of Progression of Low-Grade Dysplasia to Esophageal
Adenocarcinoma. Reported incidence of EAC in patients
withLGDhasrangedbetween0.6%and13.4%peryear,with
most studies suggesting the risk to be less than 1% per year.
Table 2 summarizes the key ﬁndings of the studies evaluating
the risk of progression of LDG to EAC [7, 14, 43–46].
10.2. Risk of Progression of High-Grade Dysplasia to
Esophageal Adenocarcinoma. Patients with HGD are at high
risk of progression to EAC [141]. Table 3 summarizes the
key ﬁndings of the studies that have evaluated the risk of
progression of HGD to EAC [47–49]. Based on the current
literature, the risk of EAC in HGD may be more than 10%
p e rp a t i e n t - y e a r[ 49, 142, 143]. The extent of HGD may alsoPathology Research International 9
Table 2: Incidence of neoplastic progression of low-grade dysplasia∗.
Study (reference) Number of BE patients followed Duration of followup Incidence of EAC/HGD
Bhat et al. [7] 8522 with BE, (no IM required) 7 years (mean) 1.4% per year (EAC)
Hvid-Jensen et al.
[14] 11,028 with BE 5.2 years (median) 0.5% per year (EAC)
Sharma et al. [43] 618 with BE; LGD diagnosed in
156 during f/u 2546 patient years (mean 4.12 years) 0.6% per year (EAC)
Lim et al. [44] 357 with BE; LGD diagnosed in
34 during f/u 8 years 9/34 cases of HGD/EAC;
3.3% per year
Schouten et al. [45] 12,0852 with BE 5.7 years (median) 0.41% per year (EAC)
Curvers et al. [46]
147 LGD patients, but only 15%
of these had a consensus
diagnosis of LGD
51.1 months (mean)
13.4% per year in those with
a consensus diagnosis of
LGD
∗Includes some of the important studies, not intended to include all studies published in the literature; f/u: followup; LGD: low-grade dysplasia; HGD: high-
grade dysplasia; EAC: esophageal adenocarcinoma.
Table 3: Incidence of esophageal adenocarcinoma in high-grade dysplasia∗.
Study (reference) Number of patients with HGD Duration of followup Incidence of EAC
Schnell et al. [47] 75 HGD patients who didn’t have EAC after 1
year f/u 7.3 years (mean) 12/75 (16%) during 7 years;
2.19% per year
Weston et al. [48] 15 patients with unifocal HGD 36.8 ±23.2 months (mean) 4/15 (26.7%) during f/u;
∼8.7% per year
Rastogi et al. [49] 236 HGD patients (meta-analysis of 4 studies) 1241 patient years Crude = 5.57% per year;
weighted = 6.58% per year
∗Includes some of the important studies, not intended to include all studies published in the literature; f/u: followup; HGD: high-grade dysplasia; EAC:
esophageal adenocarcinoma.
be an important determinant of malignant potential. Diﬀuse
HGD was noted to have a 3.7-fold higher risk of progressing
to EAC compared with focal HGD in a retrospective cohort
study [144].
11. Screeningfor Barrett’sEsophagus
Approximately40%ofadultsintheUSexperiencesymptoms
of heart burn at least once a month and about 20% report
these symptoms once a week [145]. Considering, chronic
GERDs is the strongest risk factor for BE, theoretically a
largeproportionofadultUSpopulationwouldbeeligiblefor
screening for BE based on this screening criteria. However,
about 40% of the patients diagnosed with EAC do not report
chronicGERDsymptoms[6].Thus,ifchronicGERDwereto
be used as a screening criterion, close to half of the targeted
population will be missed. Despite a rapid increase in the
incidence of EAC in the past 3 decades, the absolute number
of EAC cases diagnosed annually in the United States is
approximately 10,000. This is a small percentage of patients
with chronic GERD. Even when diagnosed with BE, a vast
majority of these patients will not develop EAC during their
lifetime [47]. Multiple studies have shown that a diagnosis of
BE does not necessarily translate into an increased all-cause
mortality compared with age- and sex-matched controls. A
vast majority of patients with BE die due to causes other
than esophageal cancer (e.g., cardiovascular disease) [45,
146, 147]. There is a lack of data showing a clear beneﬁt of
screening for BE. The current position of the AGA is that
“inadequate evidence exists to endorse endoscopic screening
for BE based solely on the presence of GERD symptoms.” The
decision regarding screening should be individualized after
discussion about the beneﬁts and limitations of screening
with the patient [8]. The ACG guidelines state that “screening
for BE in general population cannot be recommended at this
time.” The use of screening in high-risk population remains
tobeestablishedandshouldthereforebeindividualized[21].
The American Society of Gastrointestinal Endoscopy (ASGE)
guidelines consider an initial screening endoscopy to be
appropriate in select patients with frequent (several times
per week), chronic, long-standing GERD (>5y e a r s ) ,w h o
are white, males, aged >50 years, and those with nocturnal
heart burn. No further screening is needed if the initial
esophagogastroduodenoscopy(EGD)isnegativeforBE[50].
The BSG and the French Society of Digestive Endoscopy
(FSDE) do not recommend routine screening for BE [9, 42,
71]. Table 4 summarizes guidelines for screening for BE by
major professional organizations.
12. Surveillanceof Patients with
Barrett’sEsophagus
Multiple studies have demonstrated that cases of EAC diag-
nosed as a result of endoscopic surveillance are associated
with an earlier stage of disease and improved survival
compared with clinically diagnosed cases [148–152]. These
data present a rationale for surveillance of patients with BE.
However, several arguments can be made to the contrary.10 Pathology Research International
Table 4: Guidelines for screening for Barrett’s esophagus by major professional organization [8, 9, 21, 42, 50].
ACG (USA) AGA (USA) ASGE (USA) BSG (England) SFED (France)
Screening of general
population No No No No No
Screening of certain high-risk
groups Individualized∗ Individualized∗ Yes† No No
ACG:AmericanCollegeofGastroenterology;AGA:AmericanGastroenterologicalAssociation;BSG:BritishSocietyofGastroenterology;SFED:FrenchSociety
of Digestive Endoscopy.
∗After careful discussion of the potential risks, beneﬁts, and limitations of screening with the patient.
†Initial screening appropriate in select patients, no further screening needed if initial EGD is normal (see text).
There are no prospective data showing survival advantage
with surveillance. The observational studies demonstrating
beneﬁt of surveillance are limited by design ﬂaws and lead
time bias. A vast majority of patients diagnosed with EAC
do not carry a prior diagnosis of BE [147, 151, 153, 154].
Currentsurveillancemethodshavelimitations.Ourabilityto
detectdysplasiaishighlydependentonadherencetorigorous
biopsy protocols. One such protocol, called the Seattle
Protocol, recommends 4 quadrant biopsies every 1-2cm
throughout the length of columnar-lined esophagus and
separate biopsies from other areas of mucosal abnormalities
such as ulcers or nodules [155, 156]. Studies have shown
that overall adherence to validated biopsy protocols among
gastroenterologists is suboptimal and decreases even further
as the length of columnar lined mucosa increases [156, 157].
Interobserver variability among expert GI pathologists in
diagnosing the presence and degree of dysplasia has been
demonstrated in multiple studies [128]. As noted above,
the overall risk of EAC in patients with BE is low, with
recent studies showing annual incidence much lower than
0.5%[14].Despitelimitationsofthescientiﬁcevidence,most
professional societies recommend endoscopic surveillance
for patients with BE. As discussed in previous sections, the
risk of EAC increases as NDBE progresses in a sequential
manner to LGD and HGD. The frequency of surveillance is
therefore based on the grade of dysplasia.
The ACG recommends that all patients with docu-
mented BE should be assessed for surveillance. The decision
should take into consideration patient’s age, likelihood of
survival over the next 5 years, and willingness to adhere
to the surveillance program after understanding the risks,
beneﬁts, and limitations of surveillance. In order to avoid
interference due to inﬂammation from reﬂux esophagitis,
patients’ symptoms of GERD should be controlled with
proton pump inhibitors (PPIs). Surveillance EGD should
include 4 quadrant biopsies from every 2cm of Barrett’s
mucosa. Separate biopsies must be taken from other areas
of mucosal abnormalities such as ulcers or nodules. Patients
with BE with no evidence of dysplasia on index endoscopy
should undergo a repeat endoscopy with protocol biopsies
within 1 year. If no dysplasia is found, surveillance should
be done every 3 years. Finding of LGD should be conﬁrmed
by an expert GI pathologist. If LGD is conﬁrmed, an upper
endoscopy should be repeated 6 months later to rule out
a higher grade of dysplasia. If this is not found to be the
case, endoscopy should be done annually until no dysplasia
is seen on 2 consecutive endoscopies. Mucosal abnormalities
(e.g., nodules) in a background of HGD should undergo
endoscopic mucosal resection (EMR) [21]. Finding of HGD
should also be conﬁrmed by an expert GI pathologist, and
an upper endoscopy with biopsies should be repeated within
3 months. Most experts agree that ﬁnding of HGD should
trigger intensive surveillance endoscopies every 3 months
and a detailed discussion with the patient about endoscopic
therapeutic options (see below). Mucosal abnormalities
(e.g., nodules) in a background of HGD should undergo
endoscopic mucosal resection (EMR) [21].
Other major gastroenterology organizations in the US
endorse mostcomponents ofACG guidelines onsurveillance
for BE. Table 5 summarizes the guidelines for surveillance of
BE by major professional organizations in the United States.
13. Management of Barrett’s Esophagus
13.1. Management of Nondysplastic Barrett’s Esophagus. All
patients with BE should be on acid-suppressive therapy
to control symptoms related to GERD. However, there is
no convincing evidence that acid-suppressive therapy or
antireﬂux surgery reverses the IM or dysplasia [8, 158].
Although endoscopic eradiation therapies (EET) have been
tried successfully in NDBE, at this time most professional
organizationsdonotrecommendEETforNDBE[8,21,159].
13.2. Management of Barrett’s with Low-Grade Dysplasia.
The conventional approach for management of LGD has
been that of careful endoscopic surveillance biopsies and
EMR for all mucosal nodules or irregularities [21]. However,
data from some studies showing relatively high malignant
risk of LGD and growing literature on safety and eﬃcacy of
endoscopic ablation therapies has sparked a debate about the
appropriate management of LGD. Those in favor of watchful
waiting view the data on high malignant risk of LGD with
skepticism. These studies are small in size, and most do
not distinguish between prevalent LGD and incident LGD.
The latter issue is important to recognize because malignant
risk may be diﬀerent between prevalent and incident LGD.
Some of the studies have lumped together HGD and EAC
as their ﬁnal outcome of interest which can skew the data
towards a higher risk. The important issue of interobserver
variability (see above) in LGD has not been addressed in
most of these studies [160] .O n ea l s on e e d st ob ec o g n i z a n t
of the phenomenon of regression reported in LGD [43]. It
is not clear whether this occurs due to initial overdiagnosis,Pathology Research International 11
Table 5: Guidelines for Barrett’s esophagus surveillance by major professional organizations in the United States.
Grade of dysplasia ACG AGA ASGE
NDBE 2 EGD within 1st year, then every
3 years if still NDBE
2 EGD within 1st year, then every
3–5 years if still NDBE
2 EGD within 1st year, then every 3
years if still NDBE
LGD†
Repeat EGD within 6 months; if
no higher-grade dysplasia, then
every 1 year
Repeat EGD within 6 months; if
no higher-grade dysplasia, then
every 6–12 months
Repeat EGD in 6 months; if no
higher-grade dysplasia, then every 1
year
HGD†£
Repeat EGD within 3 months to
rule out EAC, then every 3
months
Repeat EGD within 3 months to
rule out EAC, then every 3
months
Repeat EGD within 3 months to rule
out EAC, then every 3 months
†Should be conﬁrmed by an expert GI pathologist.
£Detailed discussion should be initiated regarding therapeutic options.
Jumbo biopsy forceps should be used to increase yield.
ACG: American College of Gastroenterology; AGA: American Gastroenterological Association; NDBE: nondysplastic Barrett’s esophagus; LGD: low-grade
dysplasia; HGD: high-grade dysplasia.
sampling errors, or true regression. Finally, the cost and
risks of endoscopic therapies need to be weighed against the
beneﬁt of treating LGD, a condition whose malignant risk
has not been clearly deﬁned at this time [161, 162].
Endoscopic therapies for LGD have been used suc-
cessfully. Those in favor of endoscopic ablation for LGD
view this therapy as safe, eﬀective, and durable. In a
trial of RFA in dysplastic BE, among the patients with
LGD, complete eradication of dysplasia was seen in 90.5%
patients who received RFA compared with 22.7% in controls
(sham procedure) (P<0.001) [163]. Complete ablation
of LGD and NDBE may also give the patients peace of
mind, although data backing this assumption are lacking.
However, radiofrequency ablation (RFA) can result in upper
GI bleeding and about 6% rate of esophageal strictures
[163]. Esophageal strictures and photosensitivity reaction
to chemosensitizing agent were reported in 36% and 69%
patients,respectively,whounderwentphotodynamictherapy
(PDT) [142]. Some experts recommend an individualized
approach based on risk startiﬁcation and patient preference.
Based on the available data, the ACG, AGA, and ASGE
guidelines do not recommend routine endoscopic ablation
for LGD at this time [8, 21, 50].
13.3. Management of Barrett’s with High-Grade Dysplasia.
Before the advent of endoscopic therapies, esophagectomy
was the primary treatment option for patients with HGD.
Data from older series showed up to 40% coexisting cancer
in patients who underwent esophagectomy for HGD [164].
However, recent studies suggest that 12.7% prevalence of
EAC in these cases may be a more accurate estimate.
If patients without any endoscopically visible lesions are
analyzed, the rate drops to about 3% [165]. Furthermore,
even in expert hands, esophagectomy carries a mortality
risk of 1–5% and morbidity risk of 30–50% [164, 166].
There are no prospective, randomized trials comparing EET
directly with esophagectomy for management of HGD or
intramucosal adenocarcinoma of the esophagus. However,
this question has been evaluated in retrospective studies.
Prasad et al. retrospectively compared data on 129 patients
who received endoscopic therapy (PDT ± adjunctive EMR)
and 70 patients who underwent esophagectomy for HGD
at their institution. The patients in the PDT group were
followed for a mean of 59 ± 2.7 months and those in the
esophagectomy group for a mean of 61 ± 5.8 months. The
overall mortality was similar in the 2 groups at the end
of followup period (9% in the PDT group versus 8.5% in
the esophagectomy group, P = 0.76) [167]. Another study
identiﬁed 742 patients with early esophageal cancer, in a
review of surveillance epidemiology and end results (SEER)
database. About 13% of these patients were treated with
endoscopic therapy and rest with surgical resection. The risk
of esophageal cancer-related mortality was similar between
the endoscopic and surgical groups (HR = 0.89; CI = 0.51−
1.56; P = 0.68) [168].
EMR is an important tool in accurate staging of the
disease that can in turn guide appropriate therapy. The
specimens obtained from EMR are larger than the mucosal
biopsies and provide a better assessment of the depth of
tumor invasion into mucosa and submucosa. Larghi and
colleagues performed EUS to stage the disease of 48 BE
patients with biopsy-proven HGD/intramucosal carcinoma.
EUS showed mucosal disease in 40 patients (25 HGD and
15 intramucosal carcinomas). Eight patients found to have
submucosal invasion on EUS were excluded. EMR was done
in the 40 patients with disease conﬁned to the mucosa.
Compared with EUS, the EMR upstaged the disease from
HGD to intramucosal carcinoma in 6/25 (24%) patients
and from intramucosal carcinoma to submucosal invasion
in 6/15 (40%) patients [169]. A systematic review showed
that EMR resulted in change of diagnosis in about 25%
of cases when compared with mucosal biopsies (upstaging
or downstaging) [170]. Role of circumferential EMR in
eradication of BE with HGD has been evaluated. In one
study, 12 patients with BE and HGD or intramucosal cancer
underwent circumferential EMR (median of 2.5 sessions,
median of 5 snare resections per session). No recurrence
of BE or cancer occurred during a median followup of
9 months. Complications included esophageal strictures in
2 patients treated successfully by bougienage, and minor
bleeding during 4/31 EMR sessions [171]. Other studies
on circumferential EMR have reported 86–100% complete
eradication rate, and recurrence of malignancy in up to 11%
cases. A high stricture rate is a limitation of this technique
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Although a variety of endoscopic ablation therapies have
been studied for eradication of HGD, the best evidence is
availableforRFAandPDT.Inamulticenter,sham-controlled
trial, 127 patients with dysplastic BE were randomized to
RFA (N = 84) or sham procedure (N = 43). Among patients
with HGD, complete eradication of dysplasia was achieved
in 81% in the ablation group compared with 19% in the
control group (P<0.001). One patient developed upper
GI hemorrhage and 5 (6%) developed esophageal stricture
in the ablation group. All complications were successfully
managed endoscopically [163]. As a separate study, in the
same population, subjects in the sham group were oﬀered
crossover to the RFA treatment after the completion of ﬁrst
12 months. All subjects were followed for 2 years from initial
enrollment. Those who had achieved complete eradication
of IM at 2 years were followed for 3 additional years with
annual surveillance EGD and biopsies. At the end of study
period, dysplasia remained eradicated in >85% patients and
intestinal metaplasia in >75% without maintenance RFA.
The authors concluded that RFA oﬀers safe, eﬀective, and
durable therapy for dysplastic BE [174].
Overholt et al. performed porﬁmer-PDT in 103 patients
with BE and used supplemental Nd:YAG laser to ablate
small areas of residual Barrett’s mucosa. Mean followup for
the 82 patients who completed the study was 58.5 months.
About 94% (60/65) patients with HGD had eradication of
dysplasia. Three (4.6%) patients developed subsquamous
adenocarcinoma. Strictures occurred in 30% patients [175].
In a multicenter, randomized trial, 208 patients with HGD
were randomized to receive PDT plus omeprazole (PORPDT
group, N = 138) or omeprazole only (OM group, N =
70). Complete ablation of HGD was seen in 106/138 (77%)
patients in the PORPDT group versus 27/70 (39%) patients
in the OM group. PORPDT group experienced photosensi-
tivity reactions in 69% patients. About 36% patients in this
group developed esophageal strictures that were managed
successfully with endoscopic dilatation [142].
ThecurrentACG guidelinesstatethattreatmentforHGD
should be individualized. Patient should be presented the
options of EET, surgical resection, or intensive surveillance.
Careful consideration should be given to patient’s prefer-
ences,surgicalrisk,andavailableexpertise.Ifesophagectomy
is planned, patient should be referred to a center of expertise
and high volume (at least 20 esophagectomies per year)
to reduce operative mortality to less than 5%. The AGA
concludes that EET is a reasonable therapeutic option for
patients with HGD, especially in those with advanced age
and comorbidities. If EET is used, any visible mucosal
abnormalities should be resected by EMR. With regards
to question of esophagectomy, AGA states that this option
should be considered in young and otherwise ﬁt patients
with HGD. The Society of Thoracic Surgeons also adopts
a position very similar to the ACG and AGA for the
management of BE with HGD [176].
The patients who undergo EET for dysplastic BE should
continue to undergo surveillance after the therapy. The
surveillance interval is dependent on the highest degree
of dysplasia documented before the ablative therapy. This
surveillance protocol should be continued until lack of
dysplasia is documented to a reasonable degree of certainty
on3consecutiveendoscopies.However,periodicsurveillance
should still be continued because of the potential of BE to
recur. The precise interval for these surveillance endoscopies
has not been clearly deﬁned at this time [21, 50].
14. Chemoprevention of Barrett’s Esophagus
14.1. Proton Pump Inhibitors. Studies have evaluated the
r o l eo fa c i da n da c i ds u p p r e s s i o ni nB E .A c i de x p o s u r eh a s
been shown to induce DNA double-strand break (DSB),
increase reactive oxygen species (ROS), andactivate MAP
kinasepathway,suggestingitspotentialroleincarcinogenesis
[177, 178]. Observational studies have reported decreased
incidence of dysplasia with chronic PPI therapy [179, 180].
In one study, 188 BE patients treated with PPI therapy
for 1–13 years were prospectively followed (mean follow-
up 5.1 years). During the study period, no decrease in the
length of BE was noted, but 48% of the patients developed
squamous islands in the BE segments. The squamous islands
correlated with the duration of PPI therapy (RR: 0.43; 95%
CI: 0.35–0.65) but not with the PPI dose. All 7 patients who
received PPI for 12-13 years developed squamous islands
[181]. Conversely, there are reports suggesting an association
betweenchronicPPIuseandincreasedriskofEAC.However,
these ﬁndings may have been confounded by the indication
for chronic PPI. Thus, the increased incidence of EAC might
have been related to the original condition for which PPI
was prescribed rather than the PPI itself [182]. In summary,
the evidence on the chemo preventive eﬀects of PPI for
BE is equivocal and not backed by prospective studies.
Nonetheless, PPI use is recommended in BE, to control the
symptoms of GERD and prevent related complications like
esophagitis and ulcerations. Higher than once daily dosing
of PPI cannot be recommended based on available data [8].
14.2. Nonsteroidal Anti-Inﬂammatory Drugs and Aspirin.
Data suggest that COX-2-derived prostaglandin E2 (PGE2)
promotes tumor growth by promoting cell proliferation,
migration, apoptosis, and angiogenesis. Inhibition of COX-2
attenuates cell growth and proliferation, inhibits angiogen-
esis, and restores apoptosis [183–185]. The cardiovascular
adverse eﬀects associated with the long-term use of selective
COX-2 inhibitors have dampened the enthusiasm about
theirroleincancerchemoprophylaxis.However,studieshave
shown that chronic use of nonsteroidal anti-inﬂammatory
drugs (NSAIDs) or aspirin can decrease the risk of colorectal
cancer, gastric cancer, and several non-GI malignancies
[186]. A systematic review of 9 studies including more
than 1800 patients evaluated the association between aspirin
or NSAIDs use and esophageal cancer. Any use of aspirin
or NSAIDs was associated with a 43% reduced risk of
esophageal cancer (odds ratio (OR) = 0.57; 95% conﬁdence
interval(CI)=0.47–0.71).FrequentuseofaspirinorNSAIDs
was associated with 46% risk reduction (OR = 0.54; CI =
0.43–0.67), whereas intermittent use was associated with
18% risk reduction (OR = 0.82; CI = 0.67–0.99). Analyzed
separately, both aspirin use (OR = 0.5; CI, 0.38–0.66) andPathology Research International 13
NSAIDs use (OR = 0.75; CI = 0.54–1.0) were associated with
reduced risk of esophageal cancer. The association between
any use of aspirin or NSAIDs and decreased cancer risk was
seen for both esophageal adenocarcinoma (OR = 0.67; CI =
0.51–0.87) and squamous cell carcinoma (OR = 0.58; CI =
0.43–0.78) [187]. Vaughan et al. prospectively followed a
cohort of 350 Barrett’s patients for 20,770 person months
(median followup 65.5 months). Current use of NSAIDs
was associated with 68% risk reduction of EAC (HR =
0.32; 95% CI = 0.14–0.76) and past use with 30% risk
reduction (HR =0.70;95%CI =0.31–1.58) [188].Inarecent
study from Netherlands, 570 BE patients were prospectively
followed for a median of 4.5 years. Use of NSAIDs (median
duration 2 months) was associated with 53% lower risk of
progression to HGD/EAC (P = 0.03) [189]. Despite the
above data, there is lack of evidence to suggest that the
chemopreventive beneﬁts of NSAIDs outweigh the potential
cardiovascular side eﬀects, risk of major GI and non-GI
bleeding, and nephrotoxicity associated with their chronic
use. Most experts agree that it is appropriate to use low-
dose aspirin in patients with BE who have a cardiovascular
indication for this medication. The concomitant use of PPI,
as is the case in most BE patients, should decrease the risk of
serious GI complications [8].
14.3. Statins. Statins exert their cholesterol-lowering eﬀect
by inhibiting the enzyme 3-hydroxy-3-methylglutaryl coen-
zyme A reductase. However, this class of drugs has also
been shown to have other pleiotropic properties. Statins
promote apoptosis and inhibit proliferation in BE cells
by reducing serum-stimulated Ras activity and inhibiting
activation of extracellular signal-regulated kinase (ERK) and
protein kinase B (Akt) [190, 191]. A case-control study
of approximately 12,000 BE patients in the Department
of Veterans’ Aﬀairs database showed that statin use was
associated with a reduction in EAC risk (HR = 0.55; 95%
conﬁdence interval, 0.36–0.86), with a signiﬁcant trend
toward greater risk reduction with longer duration of statin
use [192]. In the Dutch study mentioned above, long-term
use of statins (median duration of 5 years) was associated
with a 54% reduction in the risk of malignant progression
of BE. A combination of NSAIDs and statins was associated
withariskreductionof78%(P = 0.028)[189].Althoughthe
above studies suggest an association between statin use and
decreased cancer risk in BE, a cause-eﬀect relation cannot be
established based on the available evidence.
15. FutureDirections
BE will continue to be an area of active research in the fore-
seeable future due to areas of uncertainty and controversy.
With recent studies showing a much lower cancer risk in BE,
and the growing emphasis on health care cost containment,
the rationale of screening and surveillance for BE, is likely
to come under greater scrutiny [193]. More research is
anticipated on the development of less invasive and more
cost-eﬀective modalities for detection of BE. Further studies
are needed on non-endoscopic means for BE diagnosis such
as cytosponge with immunohistochemistry, spectroscopy
andcolorimetrictechniques[194–196].Apanelofmolecular
biomarkers that can stratify patients based on risk of
progression to cancer might help develop a more tailored
approach to BE surveillance [15]. The current limitations
of high-resolution white light endoscopy and protocol
biopsies in detecting dysplasia call for continued research
on better techniques for optical recognition of dysplasia
(e.g., confocal laser endomicroscopy, spectroscopy, optical
coherence tomography, chromoendoscopy, etc.) to guide
targeted biopsies for a higher diagnostic yield [197–200].
Debate is likely to intensify on the appropriate management
of LGD and even NDBE as the safety, eﬀectiveness, and
durability of endoscopic ablation of BE is better deﬁned
[71, 160, 174, 201]. Finally, the chemoprevention of BE is
likely to remain an active area of research.
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